NeoGenomics(DE:NG9)
€15.06-0.46 (-2.96%)
DE:NG9
NeoGenomics stock forecast
€15.06
At close:-0.46 (-2.96%)
NeoGenomics (NG9) Stock Forecast & Price Target
0 Followers
NG9 Analyst Ratings
Strong Buy
7Buy2Hold0Sell
Based on 9 analysts giving stock ratings to NeoGenomics in the past 3 months
NG9 Stock 12 Month Forecast
Average Price Target
€22.05▲(46.44% Upside)Based on 9 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is EUR 22.05 with a high forecast of EUR 31.22 and a low forecast of EUR 17.84. The average price target represents a 46.44% change from the last price of EUR 15.06.
Past 12 Months12 Month ForecastJan2026Oct2026
High€31.22
Average€22.05
Low€17.84
Highest Price TargetHighest€31.22Average Price Target€22.05Lowest Price TargetLowest€17.84
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| David Westenberg | Piper Sandler | €18.73→€21.41 | buy | 42.21%Upside | Reiterated | 10/30/26 | ||
| Michael Matson | Needham | €19.63 | buy | 30.36%Upside | Reiterated | 10/29/26 | ||
| Puneet Souda | Leerink Partners | €31.22 | buy | 107.38%Upside | Reiterated | 10/29/26 | ||
| Tycho Peterson | Jefferies | €14.72→€18.73 | buy | 24.43%Upside | Reiterated | 10/29/26 | ||
| Daniel Brennan | TD Cowen | €16.95→€20.52 | buy | 36.28%Upside | Reiterated | 10/29/26 | ||
| Lu Li | Bank of America Securities | ― | hold | ― | Reiterated | 10/29/26 | ||
| Mark Massaro | BTIG | €24.98 | buy | 65.91%Upside | Upgraded | 10/06/26 | ||
| Bruce Jackson | StoneX | €14.27→€17.84 | buy | 18.51%Upside | Reiterated | 10/06/26 | ||
| Matt Larew | William Blair | ― | hold | ― | Reiterated | 10/06/26 | ||
| William Bonello | Craig-Hallum | €15.16→€16.95 | buy | 12.58%Upside | Reiterated | 07/29/26 | ||
 Unknown AnalystNot Ranked | Stephens | €13.83 | buy | -8.16%Downside | Reiterated | 04/29/26 | ||
| Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 02/17/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| David WestenbergPiper Sandler | BuyReiterated€18.73→€21.41 | 10/30/26 | 42.21%Upside | ||
| Michael MatsonNeedham | BuyReiterated€19.63 | 10/29/26 | 30.36%Upside | ||
| Puneet SoudaLeerink Partners | BuyReiterated€31.22 | 10/29/26 | 107.38%Upside | ||
| Tycho PetersonJefferies | BuyReiterated€14.72→€18.73 | 10/29/26 | 24.43%Upside | ||
| Daniel BrennanTD Cowen | BuyReiterated€16.95→€20.52 | 10/29/26 | 36.28%Upside | ||
| Lu LiBank of America Securities | HoldReiterated | 10/29/26 | ― | ||
| Mark MassaroBTIG | BuyUpgraded€24.98 | 10/06/26 | 65.91%Upside | ||
| Bruce JacksonStoneX | BuyReiterated€14.27→€17.84 | 10/06/26 | 18.51%Upside | ||
| Matt LarewWilliam Blair | HoldReiterated | 10/06/26 | ― | ||
| William BonelloCraig-Hallum | BuyReiterated€15.16→€16.95 | 07/29/26 | 12.58%Upside | ||
| Unknown AnalystStephensNot Ranked | BuyReiterated€13.83 | 04/29/26 | -8.16%Downside | ||
| Unknown AnalystGuggenheimNot Ranked | HoldReiterated | 02/17/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering NeoGenomics
3 Months
Success Rate11/23 ratings generated profit
48%
Average Return
+3.37%
Copying David Westenberg's trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of +3.37% per trade.
1 Year
Success Rate13/23 ratings generated profit
57%
Average Return
+22.37%
Copying David Westenberg's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +22.37% per trade.
2 Years
Success Rate14/23 ratings generated profit
61%
Average Return
+23.86%
Copying Michael Matson's trades and holding each position for 2 Years would result in 60.87% of your transactions generating a profit, with an average return of +23.86% per trade.
NG9 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 2 | 2 |
| Buy | 7 | 9 | 8 | 9 | 7 |
| Hold | 4 | 4 | 4 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 11 | 13 | 12 | 16 | 13 |
In the current month, NG9 has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NG9 average Analyst price target in the past 3 months is 22.05.
NG9 Financial Forecast
High€0.08
Consensus€0.06
Low€0.04
NG9 Earnings Forecast
Next quarter’s earnings estimate for NG9 is EUR 0.06 with a range of EUR 0.04 to EUR 0.08. The previous quarter’s EPS was EUR 0.06. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€189M
Consensus€189M
Low€188M
NG9 Sales Forecast
Next quarter’s sales forecast for NG9 is EUR 188.57M with a range of EUR 187.75M to EUR 189.10M. The previous quarter’s sales results were EUR 187.36M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
NG9 Stock Forecast FAQ
What is DE:NG9’s average 12-month price target, according to analysts?
Based on analyst ratings, NeoGenomics’s 12-month average price target is €22.05.
What is DE:NG9’s upside potential, based on the analysts’ average price target?
NeoGenomics has 46.44% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NeoGenomics a Buy, Sell or Hold?
NeoGenomics has a consensus rating of Strong Buy, which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
What is NeoGenomics’s share price target?
The average share price target for NeoGenomics is €22.05. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €31.22, and the lowest forecast is €17.84. The average share price target represents a 46.44% increase from the current price of €15.055.
What do analysts say about NeoGenomics?
NeoGenomics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of NeoGenomics?
To buy shares of DE:NG9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
